The following information is disclosed in accordance with Rule 26 of the AIM Rules which govern companies listed on the London Stock Exchange’s AIM market.
Description of the Business
Click here for a description of our business.
We are committed to high standards of corporate governance, business integrity and professionalism in all our activities. Click here to read about our corporate governance.
Directors and Committees
Click here to view our Board of Directors.
Click here for information on our Board Committees.
Country of Incorporation and Main Country of Operation
Akers Biosciences, Inc. is incorporated in the United States which is also our main country of operation. The rights of shareholders are different from the rights of shareholders in a UK-incorporated company.
Akers Biosciences, Inc. is not subject to the UK Takeover Code.
Current Constitutional Documents
Certificate of Amendment to the Certificate of Incorporation – 2013
Certificate of Amendment to the Certificate of Incorporation – 2008
Articles of Incorporation – 2002
Details of Exchanges
Akers Biosciences, Inc.’s shares are traded on both the AIM market of the London Stock Exchange and the NASDAQ Capital Market in the United States.
Securities in Issue
There are currently 8,891,245 common shares in issue and, insofar as the company is aware, the percentage of shares not in public hands is 8.51%.
Click here for the identity and percentage holdings of our significant shareholders.
Click here to view our latest financial reports.
Click here to view all RNS announcements.
Click here to view US SEC Filings including AGM proxy forms.
Click here to access our AIM Admission Document from May 2002.
Please note due to the length of time since its publication, this document is substantially out of date. For more up-to-date information please refer to more recent documents such as our latest Annual Report or our NASDAQ registration Form S-1 from January 2014.
Click here for a list of our advisors.
The information in this section was last updated on May 11, 2017